A clinical trial update dated July 13, 2026 reports on the study titled "Kisspeptin Administration Subcutaneously to Patients With IHH." The trial, registered as NCT05896293, is listed as a Phase 2 study. Its current status is recruiting, according to the ClinicalTrials.gov record.
The trial is evaluating subcutaneous administration of kisspeptin in patients with IHH, as stated in the study title. No outcome data or results have been reported for this trial at this time. The listing confirms only the study's design phase and its current recruitment status as of the date noted.
Kisspeptin remains classified as an unapproved compound used in research settings. This trial update does not include any efficacy or safety findings beyond the recruiting status itself. Readers should not interpret an active trial listing as evidence of any particular outcome.
Further details on trial design, eligibility, and enrollment can be found directly through the ClinicalTrials.gov registration. For more background on this compound, see the linked compound overview.